Lead Product(s): Empagliflozin
Therapeutic Area: Nephrology
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 12, 2020
The EMPA-KIDNEY clinical study is evaluating Jardiance for the progression of kidney disease and the occurrence of cardiovascular death in adults with established CKD with and without diabetes.